Saturday, 31 October 2026European Markets

NORDIC SEMICONDUC Stock Is 18% Down So Far On Tuesday

Loading stream...

(VIANEWS) - Shares of NORDIC SEMICONDUC (Oslo Børs All-share Index_GI: NOD.OL) slid by a staggering 18.82% to $138.00 at 11:35 EST on Tuesday, following the last session's downward trend. Oslo Børs All-share Index_GI is jumping 0.84% to $1,377.27, after sequential sessions in a row of losses. This seems, up until now, a somewhat up trend trading session today.

NORDIC SEMICONDUC's last close was $174.40, 30.35% under its 52-week high of $250.40.

About NORDIC SEMICONDUC

Nordic Semiconductor ASA, a fabless semiconductor company, designs, develops, markets, and sells integrated circuits and related solutions for short-and long-range wireless applications in Europe, the Americas, and the Asia/Pacific. It offers ultra-low power components; and develops low power cellular IoT. The company also provides Bluetooth 5 solutions; low power cellular devices for the IoT; and Bluetooth 5.1 solutions for direction finding applications. In addition, it offers Zigbee 3.0 IoT solutions; Thread solution for low-power devices; nRF9160 system-in-package; nRF52 and nRF51 series system-on-chips, as well as nRF591, nRF53, nRF52, and nRF51 series software development kits; ANT, a proprietary ultra-low power wireless solution for battery operated products; and application specific integrated circuits and related consulting services. Further, the company provides software for system development, communication stacks, and application layer software, as well as development tools for desktops. Its products are used in various applications, such as audio, automotive, beacon, computer peripherals, drug delivery, patient monitoring and alerts, smart home, healthcare, connected health and home, education, industrial automation, LED lighting, logistics/asset tracking, transportation, retail and payment, sports and fitness, toys and gaming, virtual reality and augmented reality products, wireless PC peripherals, mobile phone accessories, and consumer electronics, as well as wearables, including connected watches, jewelry, proximity tags, and smart clothes and apparels. The company was founded in 1983 and is headquartered in Trondheim, Norway.

Earnings Per Share

As for profitability, NORDIC SEMICONDUC has a trailing twelve months EPS of $6.1.

PE Ratio

NORDIC SEMICONDUC has a trailing twelve months price to earnings ratio of 22.62. Meaning, the purchaser of the share is investing $22.62 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.07%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

NORDIC SEMICONDUC's stock is considered to be oversold (<=20).

Volatility

NORDIC SEMICONDUC's last week, last month's, and last quarter's current intraday variation average was 3.52%, 0.01%, and 2.24%.

NORDIC SEMICONDUC's highest amplitude of average volatility was 3.71% (last week), 2.69% (last month), and 2.24% (last quarter).

Sales Growth

NORDIC SEMICONDUC's sales growth is 35.4% for the current quarter and 18.6% for the next.

More news about NORDIC SEMICONDUC (NOD.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com